Skip to content

Dr. Gearóid Tuohy

Researchers at Moorfields Eye Hospital have reported valuable genotype-phenotype correlations on KCNV2-associated retinopathy  

Researchers have published a study showing that genetic missense alterations on KCNV2-asscociated retinopathy may appear to hold better visual acuity and greater structural integrity (Guimaraes… Read More »Researchers at Moorfields Eye Hospital have reported valuable genotype-phenotype correlations on KCNV2-associated retinopathy  

Researchers at UCL and Moorfields Eye Hospital have reported an AI “foundation  model” for ophthalmology, published in the journal Nature.

Researchers at the Centre for Medical Image Computing, University College London, London, UK and the Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust,… Read More »Researchers at UCL and Moorfields Eye Hospital have reported an AI “foundation  model” for ophthalmology, published in the journal Nature.

Nanoscope Therapeutics Inc., have reported clinical trial results from a Phase 2 Stargardt disease study with optogenetic gene therapy. 

Nanoscope Therapeutics Inc., a company based in Bedford, Texas, has reported key results from a Phase 2 clinical trial, “STARLIGHT”, at the American Society of… Read More »Nanoscope Therapeutics Inc., have reported clinical trial results from a Phase 2 Stargardt disease study with optogenetic gene therapy. 

US & Belgium research team discover a novel “nanobody” (a “mini-antibody”) potentially applicable to retinitis pigmentosa (RP) treatment.

Researchers at the Department of Ophthalmology, University of California, Irvine and the Structural Biology Research Centre, Vrije Universiteit Brussels, Belgium, have reported the use of… Read More »US & Belgium research team discover a novel “nanobody” (a “mini-antibody”) potentially applicable to retinitis pigmentosa (RP) treatment.